Matthew K. Robinson Ph.D. Net Worth

Mr. Matthew K. Robinson Ph.D. biography

Matthew K. Robinson Ph.D. is the Sr. VP of R&D at Immunome.

What's Mr D's mailing address?

Matthew's mailing address filed with the SEC is C/O IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300, EXTON, PA, 19341.

Insiders trading at Immunome

Over the last 4 years, insiders at Immunome have traded over $0 worth of Immunome stock and bought 480,004 units worth $5,722,735 . The most active insiders traders include Clay B Siegall, Jean Jacques Bienaime e Michael Rapp. On average, Immunome executives and independent directors trade stock every 84 days with the average trade being worth of $518,362. The most recent stock trade was executed by Jean Jacques Bienaime on 15 August 2024, trading 7,000 units of IMNM stock currently worth $97,580.

What does Immunome do?

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Immunome executives and stock owners

Immunome executives and other stock owners filed with the SEC include:

• Dr. Purnanand Duddu Sarma,
  Pres, CEO & Director
• Sandra G. Stoneman Esq.,
  Chief Legal Officer, Gen. Counsel & Corp. Sec.
• Dr. Michael J. Morin Ph.D.,
  Chief Scientist
• Dr. Scott K. Dessain M.D., Ph.D.,
  Co-founder & Chairman of the Scientific Advisory Board
• Dr. Dennis H. Giesing,
  Chief Devel. Officer
• Matthew K. Robinson Ph.D.,
  Sr. VP of R&D
• Corleen M. Roche,
  Chief Financial Officer
• Michael Widlitz,
  Director
• Michael Lefenfeld,
  Director
• Dennis H Giesing,
  Chief Development Officer
• Jean Jacques Bienaime,
  
• Max Rosett,
  EVP, Operations & CFO
• James P Boylan,
  
• Philip Tsai,
  Chief Technology Officer
• Franklyn G Prendergast,
  Director
• Sandra M Swain,
  
• I Wistar Iii Morris,
  10% owner
• Richard F Fitzgerald,
  Chief Financial Officer
• John L Lamattina,
  Director
• Michael Rapp,
  Director
• Corleen M. Roche,
  Chief Financial Officer
• Philip Wagenheim,
  
• Richard A Baron,
  Director
• Matthew K Robinson,
  Chief Technology Officer
• Purnanand D Sarma,
  President and CEO
• Clay B Siegall,
  President and CEO
• Isaac Barchas,
  
• Phil Noland Roberts,
  Chief Technology Officer
• Carol Schafer,
  
• Kinney Horn,
  CHIEF BUSINESS OFFICER
• Jack Higgins,
  Chief Scientific Officer
• Robert Lechleider,
  Chief Medical Officer
• Bruce Turner,
  Chief Strategy Officer